Gastric Cancer Therapy Market Report 2026

The gastric cancer therapy market size has grown strongly in recent years. It will grow from $4.5 billion in 2025 to $4.92 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited targeted therapy availability, reliance on conventional chemotherapy and surgery, growing gastric cancer prevalence, increasing hospital oncology infrastructure, awareness of early detection programs.

The gastric cancer therapy market size is expected to see strong growth in the next few years. It will grow to $6.96 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to development of novel immunotherapies and checkpoint inhibitors, rising precision medicine adoption, expansion of outpatient oncology services, increasing investment in gastric cancer research, integration of digital health tools for patient monitoring. Major trends in the forecast period include increasing adoption of targeted and personalized therapies, rising use of combination therapy approaches, growth in early detection and screening programs, expansion of home care and ambulatory treatment options, focus on reducing adverse effects and improving patient quality of life.

The growing prevalence of Helicobacter pylori infection is expected to fuel the expansion of the gastric cancer therapy market over the forecast period. Helicobacter pylori infection is a bacterial disorder that mainly affects the stomach lining and is a significant cause of chronic gastritis and gastric cancer development. The increasing incidence of Helicobacter pylori infection is largely linked to poor sanitation, as insufficient hygiene practices and contaminated food or water sources enable oral-oral or fecal-oral transmission of the bacteria. Gastric cancer therapy plays a critical role in reducing the risk of gastric cancer associated with Helicobacter pylori infection by eradicating the bacteria, decreasing gastric inflammation and cellular damage, and preventing the progression of chronic gastritis and atrophic changes that can lead to malignant transformation of the gastric mucosa. For example, in November 2024, according to a report released by the Government of Canada, a Canada-based government administration, as of January 2023, the recurrence rate of H. pylori infection was estimated to be as high as 19%, with variation depending on geographic region and age group. As a result, the rising prevalence of Helicobacter pylori infection is supporting the growth of the gastric cancer therapy market.

Key companies operating in the gastric cancer therapy market are prioritizing the development of innovative treatment strategies, such as combination therapy, to improve therapeutic efficacy and patient outcomes. Combination therapy refers to the use of two or more treatment approaches, including chemotherapy, targeted therapy, or immunotherapy, to enhance overall effectiveness. For instance, in December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, received approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). This approval was based on results from the Phase 3 RATIONALE-305 trial, which demonstrated that the combination therapy extended median overall survival to 15 months, compared with 12.9 months achieved with chemotherapy alone, representing a 20% reduction in the risk of death. This advancement highlights an increasing focus among major pharmaceutical companies on investing in advanced, multimodal treatment approaches that integrate immunotherapy with conventional chemotherapy regimens to improve clinical outcomes, delay disease progression, and enhance survival rates in patients with advanced gastric cancer.

In January 2023, Leap Therapeutics Inc., a US-based biotechnology company, acquired Flame Biosciences Inc. for an undisclosed amount. Through this acquisition, Leap Therapeutics aimed to strengthen its oncology pipeline by incorporating Flame Biosciences’ clinical-stage anti-Claudin18.2 antibody FL-301 along with two preclinical antibody programs, thereby advancing the development of biomarker-targeted cancer therapies. Flame Biosciences Inc. is a US-based biotechnology company specializing in the development of gastric cancer therapies.

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.

North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the gastric cancer therapy market by increasing costs of imported drugs, monoclonal antibodies, and specialized medical equipment. Segments such as targeted therapy and immunotherapy are most affected, with regions like North America and Asia-Pacific facing higher import duties and supply chain disruptions. While tariffs raise treatment costs and limit accessibility in some areas, they also encourage local pharmaceutical manufacturing and investment in domestic production capabilities, fostering innovation and self-reliance in key markets.

The gastric cancer therapy market research report is one of a series of new reports that provides gastric cancer therapy market statistics, including gastric cancer therapy industry global market size, regional shares, competitors with a gastric cancer therapy market share, detailed gastric cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer therapy industry. This gastric cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric cancer therapy refers to the medical treatment strategies used to manage and treat cancer arising in the stomach lining, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, which may be used alone or in combination depending on the stage of the disease and tumor-specific features. These treatments operate through mechanisms such as eliminating rapidly dividing cancer cells, interfering with specific molecular pathways that promote tumor growth, or enhancing the immune system’s ability to identify and destroy cancer cells.

The main categories of gastric cancer therapy include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy involves the use of medications designed to kill fast-growing cancer cells throughout the body. These medications are classified into cytotoxic agents, monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, and miscellaneous agents, and can be administered through several routes, including oral, intravenous, intramuscular, and subcutaneous. These therapies are applied at different stages of the disease, including early stage, locally advanced stage, and metastatic stage, and are utilized by a range of end users such as hospitals, oncology clinics, ambulatory surgical centers, research institutions, and home care settings.

The gastric cancer therapy market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, supportive care and palliative services, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer therapy market also includes sales of trastuzumab (Herceptin), nivolumab (Opdivo), ramucirumab (Cyramza), and fluorouracil-based chemotherapy, and endoscopic devices and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.